Business
Elevar Therapeutics Announces FDA Acceptance of New Drug Application Resubmission for Rivoceranib in Combination with Camrelizumab as a First-line Systemic Treatment for Unresectable Hepatocellular Carcinoma
FDA sets PDUFA target action date of July 23, 2026FORT LEE, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, today announced the U.S. Food and Drug Administration (FDA) accepted the resubmission of a new drug application (NDA) for its investigational drug rivoceran
About this update from Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class A
[{"type":"image","alt":"Elevar Therapeutics","displaySize":"","headline":null,"caption":"Elevar Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":161,"url":"https://media.zenfs.com/en/globenewswire.com/a2770d8ef03e07518cdc9afb63f932c5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/LJapUQXqQ2gz90Ut7I6oDQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/a2770d8ef03e07518cdc9afb63f932c5","width":300,"height":161}},"lazy":false},{"type":"text","content":"FDA sets PDUFA target action date of July 23, 2026","length":50,"tagName":"p"},{"type":"text","content":"FORT LEE, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, today announced the U.S. Food and Drug Administration (FDA) accepted the resubmission of a new drug application (NDA) for its investigational drug rivoceranib, an oral VEGF-TKI, in combination with camrelizumab, an anti-PD-1 antibody, as a first-line systemic treatment for unresectable or metastatic hepatocellular carcinoma (uHCC). The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action date of July 23, 2026. HCC is the most common type of liver cancer.","length":767,"tagName":"p"},{"type":"text","content":"Elevar on Jan. 23, 2026, submitted the NDA for rivoceranib, while Hengrui Pharma submitted a biologics license application (BLA) for camrelizumab. The FDA will review the applications under an integrated review process, as the two agents combine to form a single-therapy regimen. The resubmission was based on the FDA’s request for additional information raised in its Complete Response Letter issued on March 20, 2025. The new applications fully address the previously raised concerns.","length":486,"tagName":"p"},{"type":"text","content":"“We will continue to work closely with Hengrui to ensure full readiness throughout the FDA review process, including the inspection of relevant manufacturing facilities,” said Dong-Gun Kim, Chief Executive Officer of Elevar Therapeutics. “We will also maintain proactive communication with the FDA and remain focused on achieving a successful outcome.”","length":352,"ta...
More updates from Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class A